Evidence map›Paper›PMID 36778431›Full record

ArticlemedRxiv : the preprint server for health sciences2023

Effect of Pathway-specific Polygenic Risk Scores for Alzheimer's Disease (AD) on Rate of Change in Cognitive Function and AD-related Biomarkers among Asymptomatic Individuals.

Yuexuan Xu, Eva Vasiljevic, Yuetiva K Deming, Erin M Jonaitis, Rebecca L Koscik, Carol A Van Hulle, Qiongshi Lu, Margherita Carboni, Gwendlyn Kollmorgen, Norbert Wild and 5 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 5 countries.

Yuexuan XuDepartment of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, WI, USA.
Eva VasiljevicDepartment of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, WI, USA.
Yuetiva K DemingDepartment of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, WI, USA.
Erin M JonaitisWisconsin Alzheimer's Institute, University of Wisconsin-Madison, WI, USA.
Rebecca L KoscikDepartment of Medicine, School of Medicine and Public Health, University of Wisconsin-Madison, WI, USA.
Carol A Van HulleDepartment of Medicine, School of Medicine and Public Health, University of Wisconsin-Madison, WI, USA.
Qiongshi LuDepartment of Biostatistics and Medical Informatics, School of Medicine and Public Health, University of Wisconsin-Madison, WI, USA.
Margherita CarboniRoche Diagnostics International Ltd, Rotkreuz, Switzerland.
Gwendlyn KollmorgenRoche Diagnostics GmbH, Penzberg, Germany.
Norbert WildRoche Diagnostics GmbH, Penzberg, Germany.
Cynthia M CarlssonDepartment of Medicine, School of Medicine and Public Health, University of Wisconsin-Madison, WI, USA.
Sterling C JohnsonDepartment of Medicine, School of Medicine and Public Health, University of Wisconsin-Madison, WI, USA.
Henrik ZetterbergDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden.
Kaj BlennowDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden.
Corinne D EngelmanDepartment of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, WI, USA.
University of Wisconsin System · USUniversity of Wisconsin–Madison · USRoche Pharma AG (Germany) · DESahlgrenska University Hospital · SERoche (Switzerland) · CH

Funding

University of Wisconsin Institute for Clinical and Translational ResearchUL1TR002373 · NCATS · UNIVERSITY OF WISCONSIN-MADISON · PI ELIZABETH S BURNSIDE, Allan R. Brasier · 2017 to 2026
$75.9M
Wisconsin Registry for Alzheimer's Prevention: Sex Differences in DNA MethylationR01AG027161 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI Nathaniel Ark Chin, Sterling C Johnson · 2007 to 2026
$35.6M
Wisconsin Alzheimer's Disease Research CenterP30AG062715 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI AMY J. KIND · 2019 to 2026
$34.5M
Institutional Clinical and Translational Science AwardUL1TR000427 · NCATS · UNIVERSITY OF WISCONSIN-MADISON · PI DREZNER, MARC KENNETH · 2012 to 2016
$32.2M
Statistical Data Enclave CoreP30AG017266 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI Michal Engelman · 1999 to 2026
$17.0M
Biology of Aging and Age-Related Diseases Training GrantT32AG000213 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI Rozalyn M. Anderson, Sanjay Asthana · 1991 to 2026
$9.9M
Scientific and Technical CoreP2CHD047873 · NICHD · UNIVERSITY OF WISCONSIN-MADISON · PI Katherine J. Curtis · 2014 to 2026
$5.1M
Genomic and Metabolomic Data Integration in a Longitudinal Cohort at Risk for Alzheimer's DiseaseR01AG054047 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI ENGELMAN, CORINNE D. · 2016 to 2020
$3.6M
Identifying Metabolomic Risk Factors in Plasma and Cerebrospinal Fluid for Alzheimer's DiseaseR21AG067092 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI LU, QIONGSHI · 2020 to 2020
$375k
NCATS NIH HHS UL1 TR000427NCATS NIH HHS UL1 TR002373NIA NIH HHS P30 AG017266NIA NIH HHS P30 AG062715NIA NIH HHS R01 AG027161NIA NIH HHS R01 AG054047NIA NIH HHS R21 AG067092NIA NIH HHS T32 AG000213NICHD NIH HHS P2C HD047873
6 · The paper itself

Abstract

Background: Genetic scores for late-onset Alzheimer's disease (LOAD) have been associated with preclinical cognitive decline and biomarker variations. Compared with an overall polygenic risk score (PRS), a pathway-specific PRS (p-PRS) may be more appropriate in predicting a specific biomarker or cognitive component underlying LOAD pathology earlier in the lifespan. Objective: In this study, we leveraged 10 years of longitudinal data from initially cognitively unimpaired individuals in the Wisconsin Registry for Alzheimer's Prevention and explored changing patterns in cognition and biomarkers at various age points along six biological pathways. Methods: PRS and p-PRSs with and without apolipoprotein E ( Results: We found p-PRSs and the overall PRS can predict preclinical changes in cognition and biomarkers. The effects of p-PRSs/PRS on rate of change in cognition, beta-amyloid, and tau outcomes are dependent on age and appear earlier in the lifespan when Conclusion: In addition to

Identifiers

PMID36778431
PMCPMC9915839
OpenAlexW4319036005

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.